BIOAGE Labs Inc (BIOA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 91.55 is considered Overvalued compared with the five-year average of -2.99. The fair price of BIOAGE Labs Inc (BIOA) is between 2.60 to 13.69 according to relative valuation method. Compared to the current price of 21.72 USD , BIOAGE Labs Inc By Overvalued By 58.6%.

Relative Value

Fair Zone

2.60-13.69

Current Price：21.72

58.6%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BIOAGE Labs Inc (BIOA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BIOAGE Labs Inc (BIOA) has a current Price-to-Book (P/B) ratio of 1.66. Compared to its 3-year average P/B ratio of 0.73, the current P/B ratio is approximately 127.31% higher. Relative to its 5-year average P/B ratio of 0.73, the current P/B ratio is about 127.31% higher. BIOAGE Labs Inc (BIOA) has a Forward Free Cash Flow (FCF) yield of approximately -12.86%. Compared to its 3-year average FCF yield of -27.17%, the current FCF yield is approximately -52.67% lower. Relative to its 5-year average FCF yield of -27.17%, the current FCF yield is about -52.67% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BIOA competitors is 30.87, providing a benchmark for relative valuation. BIOAGE Labs Inc Corp (BIOA.O) exhibits a P/S ratio of 91.55, which is 196.55% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BIOA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BIOA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BIOA currently overvalued or undervalued?

What is BIOAGE Labs Inc (BIOA) fair value?

BIOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BIOAGE Labs Inc (BIOA) is between 2.60 to 13.69 according to relative valuation method.

How does BIOA's valuation metrics compare to the industry average?

The average P/S ratio for BIOA's competitors is 30.87, providing a benchmark for relative valuation. BIOAGE Labs Inc Corp (BIOA) exhibits a P/S ratio of 91.55, which is 196.55% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for BIOAGE Labs Inc (BIOA) as of Mar 02 2026?

As of Mar 02 2026, BIOAGE Labs Inc (BIOA) has a P/B ratio of 1.66. This indicates that the market values BIOA at 1.66 times its book value.

What is the current FCF Yield for BIOAGE Labs Inc (BIOA) as of Mar 02 2026?

As of Mar 02 2026, BIOAGE Labs Inc (BIOA) has a FCF Yield of -12.86%. This means that for every dollar of BIOAGE Labs Inc's market capitalization, the company generates -12.86 cents in free cash flow.

What is the current Forward P/E ratio for BIOAGE Labs Inc (BIOA) as of Mar 02 2026?

As of Mar 02 2026, BIOAGE Labs Inc (BIOA) has a Forward P/E ratio of -4.76. This means the market is willing to pay $-4.76 for every dollar of BIOAGE Labs Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BIOAGE Labs Inc (BIOA) as of Mar 02 2026?

As of Mar 02 2026, BIOAGE Labs Inc (BIOA) has a Forward P/S ratio of 91.55. This means the market is valuing BIOA at $91.55 for every dollar of expected revenue over the next 12 months.

BIOA Valuation